• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Hematology

Routine primary thromboprophylaxis with enoxaparin safe in children with COVID-19 or MIS-C

byVincent SoandAlex Gipsman, MD
July 12, 2022
in Hematology, Infectious Disease, Pediatrics
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

 1. Routine use of prophylactic twice-daily enoxaparin demonstrated adequate safety in children with acute COVID-19 and multisystem inflammatory syndrome in children (MIS-C).

2. Target anti-Xa levels were generally achieved with a dose of 0.5 mg/kg for all ages.

Evidence Rating Level: 2 (Good)

Study Rundown: Most children infected with COVID-19 experience only mild illness; however, both acute COVID-19 and MIS-C can cause a pro-thrombotic state and are associated with an increased risk of hospital-acquired venous thromboembolism (HA-VTE). Despite recommendations for routine thromboprophylaxis for hospitalized adults with COVID-19, there is insufficient evidence to support thromboprophylaxis in the pediatric population. In this prospective, single-arm study that included 38 patients, researchers evaluated the safety of twice-daily enoxaparin for primary thromboprophylaxis in children hospitalized with COVID-19 or MIS-C to prevent HA-VTE within 30 days of hospital discharge. Overall, there was no clinically significant bleeding observed. 2 participants developed HA-VTE, and 1 death occurred due to underlying COVID-19 illness. Important limitations of this study include an open-label study design and small sample size. Nonetheless, this phase 2 trial is one of few available studies assessing the use of primary thromboprophylaxis in children and provides preliminary evidence that it is safe for use in children with prolonged hospital stay. Larger studies with a randomized, placebo-controlled design are required before routinely recommending the use of enoxaparin thromboprophylaxis in patients with COVID-19 and MIS-C.

Click here to read the article in PEDIATRICS

Relevant Reading: Incidence of venous thromboembolism and mortality in patients with initial presentation of COVID-19

In Depth [Prospective Cohort]: Researchers performed a phase 2, multi-center, prospective, single-arm clinical trial that included 38 patients. The study included data from 8 sites across United States. Of the 38 patients, 18 patients were diagnosed with primary COVID-19 and 20 patients were diagnosed with MIS-C. Patients received enoxaparin at starting doses of 0.5 mg/kg adjusted to achieve a 4-hour post-administration anti-Xa level between 0.20-0.49 U/mL. Of the 38 children enrolled, 35 (92.1%) achieved target anti-Xa levels and 28 (74.7%) did not require dose adjustments after the first administered dose. Median dose to achieve target anti-Xa levels was 0.5 mg/kg (0.48–0.54) and did not differ by age. However, levels of enoxaparin required to achieve target anti-Xa levels was higher in patients with MIS-C (0.52 [0.5–0.61] mg/kg) as compared with primary COVID-19 (0.48 [0.39–0.51] mg/kg, p=0.01). MIS-C patients were younger in age (p<0.001), had lower BMI (p=0.004), lower hemoglobin levels (p=0.002), and higher D-dimer levels (p=0.001). Additionally, they were more likely to received corticosteroids (p=0.04) and MIS-C (p<0.001). Primary COVID-19 patients were more likely to receive remdesivir (p<0.001).

RELATED REPORTS

Delta variant of SARS-CoV-2 infection associated with higher changes of severe maternal morbidities

The CDC implements a community-level metrics program to inform COVID-19 policy

Concentration of SARS-CoV-2 antibodies in COVID-19 recovered women

Image: PD

©2022 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: COVID-19enoxaparinMIS-Cthromboprophylaxisvenous thromboembolism (VTE)
Previous Post

Inappropriate sleep duration may influence the economic burden of health care

Next Post

5-day versus 10-day course of remdesivir in patients with severe COVID-19 [Classics Series]

RelatedReports

Novel coronavirus identified from patients with pneumonia in Wuhan, China
Infectious Disease

Delta variant of SARS-CoV-2 infection associated with higher changes of severe maternal morbidities

August 17, 2022
ACP offers recommendations to improve the ACA, patient care
Chronic Disease

The CDC implements a community-level metrics program to inform COVID-19 policy

August 17, 2022
Fewer work hours linked to greater likelihood of continued breastfeeding
Infectious Disease

Concentration of SARS-CoV-2 antibodies in COVID-19 recovered women

August 16, 2022
Characteristic differences between young children and adolescents who die by suicide
Weekly Rewinds

2 Minute Medicine Rewind August 8, 2022

August 15, 2022
Next Post
The ABCD2 score: Risk of stroke after Transient Ischemic Attack (TIA) [Classics Series]

5-day versus 10-day course of remdesivir in patients with severe COVID-19 [Classics Series]

#VisualAbstract: Pembrolizumab reduces disease recurrence in completely resected stage IIB/IIC melanoma

#VisualAbstract: Pembrolizumab reduces disease recurrence in completely resected stage IIB/IIC melanoma

Open carpal tunnel release provides long-term symptom relief

Use of soft bandage is comparable to rigid immobilization for distal radius torus fractures in children

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Delta variant of SARS-CoV-2 infection associated with higher changes of severe maternal morbidities
  • Endoscopic sleeve gastroscopy effective for excess weight loss in type 1 and 2 obesity
  • #VisualAbstract: Early time-restricted eating was more effective for weight loss than eating over 12-hour window
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.